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Abstract
Merkel Cell Polyomavirus (MCPyV) is associated with Merkel Cell carcinoma (MCC), a rare, aggressive skin cancer with
neuroendocrine features. The causal role of MCPyV is highly suggested by monoclonal integration of its genome and
expression of the viral large T (LT) antigen in MCC cells. We investigated and characterized MCPyV molecular features in
MCC, respiratory, urine and blood samples from 33 patients by quantitative PCR, sequencing and detection of integrated
viral DNA. We examined associations between either MCPyV viral load in primary MCC or MCPyV DNAemia and survival.
Results were interpreted with respect to the viral molecular signature in each compartment. Patients with MCC containing
more than 1 viral genome copy per cell had a longer period in complete remission than patients with less than 1 copy per
cell (34 vs 10 months, P=0.037). Peripheral blood mononuclear cells (PBMC) contained MCPyV more frequently in patients
sampled with disease than in patients in complete remission (60% vs 11%, P=0.00083). Moreover, the detection of MCPyV
in at least one PBMC sample during follow-up was associated with a shorter overall survival (P=0.003). Sequencing of viral
DNA from MCC and non MCC samples characterized common single nucleotide polymorphisms defining 8 patient specific
strains. However, specific molecular signatures truncating MCPyV LT were observed in 8/12 MCC cases but not in respiratory
and urinary samples from 15 patients. New integration sites were identified in 4 MCC cases. Finally, mutated-integrated
forms of MCPyV were detected in PBMC of two patients with disseminated MCC disease, indicating circulation of metastatic
cells. We conclude that MCPyV molecular features in primary MCC tumour and PBMC may help to predict the course of the
disease.
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Introduction
Polyomaviruses are small, non enveloped double stranded DNA
viruses which infect many species with a restricted host range. The
initial discovery of Murine polyomavirus (MPyV) and Simian
vacuolating 40 (SV40) was closely linked to the demonstration of
their experimental tumorigenic properties [1]. Infections by the
human polyomaviruses BK (BKPyV), JC (JCPyV), and the
recently identified KI (KIPyV) and WU (WUPyV) are highly
prevalent in most populations [2,3]. Polyomaviruses persist
latently in the host and may reactivate, causing disease in the
immunocompromised [4,5], but have not been firmly associated
with cancer in humans [6]. Therefore, the discovery in a rare but
aggressive skin cancer, Merkel Cell Carcinoma (MCC), of a fifth
human Polyomavirus, named Merkel Cell Polyomavirus (MCPyV)
has raised new interest in the oncogenic potential of human
Polyomaviruses [7]. MCPyV DNA was shown to be monoclonally
integrated into most MCC, and tumour cells were found to express
the major viral oncoprotein, large T antigen (LT) [8]. Remark-
ably, MCPyV present in MCC tissue exhibited a molecular
signature, consisting of mutations which truncate LT and suppress
its helicase domain required for viral replication [9]. These
features are similar to molecular defects observed in MPyV [10]
and bring strong evidence for a causative role of the virus in MCC.
MCC is a carcinoma of neuroendocrine cells which affects
principally elderly and immunocompromised patients. The close
association between MCPyV and MCC has been confirmed in
several case series worldwide [11,12,13,14,15,16,17,18,19,20,
21,22]. However, MCPyV has been detected in normal skin
[23], benign skin lesions [24] and non MCC skin cancer [25], and
also found in various tissues such as the oral cavity [26],
gastrointestinal and urogenital tracts [23], tonsils [27], respiratory
tract [28], blood [9], and rarely in non skin cancers [19,25,29,30].
Seroepidemiologic studies have revealed that most healthy
individuals are infected with MCPyV, as with other human
Polyomaviruses [31,32,33,34,35]. Therefore, numerous questions
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mechanisms of oncogenesis remain unanswered. We investigated
whether MCC patients’ clinical data were related to the presence of
MCPyV and specific molecular features in tumour and non tumour
tissues. In a cohort of 33 MCC patients, we collected MCC and non
MCC samples, and compared the frequencies of MCPyV DNA
detection, viral load and nucleotide sequences. We looked for
integration of MCPyV in MCC cells and for the presence of
integrated/mutated forms of MCPyV in non tumour samples.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. According to French regulation,
information was delivered to the patients on research performed
on biological samples, and written informed consent was obtained
for participation in the study, which was approved by the
institutional review board of the Comite ´ de protection des
personnes Ile de France 3.
Patients and samples
All patients with Merkel cell carcinoma who attended the
Dermatology Departments of Cochin and Bichat hospitals from
March 2008 to April 2010 were prospectively included in the study.
Histopathologic confirmation of MCC diagnosis relied on tumour
morphology consistent with MCC on hematoxylin-eosin-stained
tissue sections, paranuclear dot immunostaining pattern for CK20
orpositiveimmunostainingforsynaptophysinand chromograninA.
Clinical data were retrieved from hospital case records, and
included sex, age at diagnosis, site and size of primary MCC, and
stage of the disease at diagnosis, according to Allen’s classification
[36] based on primary tumour diameter (,2c m=I ,.2 cm = II)
and the presence of metastasis (regional lymph node metastasis =
III, distant = IV). Samples from primary and/or metastatic MCC
lesions were recovered and included retrospectively retrieved
formalin-fixed paraffin-embedded (FFPE) sections and/or fresh-
frozen specimens for patients newly diagnosed or who relapsed.
FFPE sections from non MCC cancer tissue were retrieved if
possible. In addition, blood and/or nasal swab and/or urine were
sampled in patients at inclusion and follow-up visits when possible,
and disease stage and status were recorded. Status was defined
according to the presence or absence of tumour (primary and/or
metastatic) as alive with disease (AWD) or in complete remission
(CR) respectively. Date and cause of death were recorded.
Detection and quantification of MCPyV sequences in
MCC and non MCC samples
For FFPE samples, two consecutive 10 m-thick sections were
retrieved. Frozen fragments were cut and mechanically dissociat-
ed. DNA was extracted using the QIAmp DNA tissue extraction
kit (Qiagen) according to the manufacturer instructions. Nasal
swabs discharged in 200 ml sterile saline buffer and urine were
immediately frozen and kept at –20uC until analysis. PBMC were
obtained by Ficollpaque centrifugation (Eurobio) of 3 mL EDTA
blood, suspended in 200 ml of PBS, immediately frozen and kept at
–20uC until analysis. DNA was extracted using the QIAmp blood
DNA extraction kit (Qiagen). For tissue material, lysis was
extended to 24 h. DNA was eluted in 200 ml elution buffer
(Macheret), and concentration was measured by UV-spectrometry
(NanoDrop Technology, Willmington).
To detectMCPyVsequences,a sensitiverealtime PCRassaywas
designed using primers which encompass a 91 bp fragment of the
LT oncoprotein gene, located upstream of the Rb-bindingencoding
sequence (Table S1) [7]. Amplification was performed on 100 ng
DNA with 300 nM each primer and 100 nM probe in 50 ml
Taqman Master Mix (Applied Biosystems, Courtaboeuf). After a
10 mindenaturationstepat95uC,cyclingconditions consisted of50
cycles of 15 sec at 95uC and 1 min at 60uC on an ABI 7500
platform (Applied Biosystems). To check for carryover between the
samples, mock samples were included in each series. Confirmation
LT3 and VP1 PCR assays were performed as described [7].
Absolute quantification of MCPyV viral load in patients’ samples
was obtained by establishing a calibration curve with ten-fold serial
dilutions (from 10 to 10
6 copies) of known concentrations of plasmid
MCCIC13 which contains 1 copy of the MCPyV genome inserted
in the pCR-XL-TOPO vector [18]. To quantify MCPyV DNA in
copy number per cell in MCC and non MCC cancer samples, the
housekeeping apolipoprotein B gene (hapb) [37] was amplified by
real time PCR and the delta-delta Ct method was used.
Detection of BKPyV and JCPyV sequences
To detect BKPyV and JCPyV sequences, real time PCR assays
were designed to amplify a 79 and a 110 bp fragment of the LT
antigen coding sequence in BKPyV and JCPyV genome
respectively (Table S1). Amplification was performed using the
same cycling and control conditions as above.
Analysis of MCPyV integration site
To characterize integration of MCPyV, we used the DIPS-PCR
technique which amplifies junctions between the host and MCPyV
genomes as previously described [18,38]. Briefly, DNA extracted
from MCC tumours was digested overnight with Taq I (Invitrogen),
an enzyme that does not cleave the MCV350 sequence (GenBank
accession number EU375803), and ligated to adapters. Ligated
fragments were subjected to 40 cycles of linear amplification with
forward primers sequentially designed along the MCPyV LT gene
(Table S1), followed by a 30 cycle exponential amplification using
internal primers coupled to a reverse adapter-specific primer. PCR
products were visualized and cut from agarose gel, purified with
QIAmp gel extraction kit (Qiagen), and directly sequenced using Big-
Dye terminator DNA-Sequencing technology (Applied Biosystems).
PCR detection of integrated and non integrated MCPyV
genome
To discriminate integrated versus non integrated forms of the
MCPyV genome in patients’ samples, we amplified short
fragments bracketing each of the characterized integration sites.
DNA (100 ng) was subjected to PCR using a forward MCPyV-
Author Summary
Merkel cell polyomavirus (MCPyV) is a recently discovered
virus highly associated with a rare skin cancer, Merkel cell
carcinoma (MCC). The causal role of MCPyV in cancer is
suggested by integration of viral sequences into the cell
genome and by a specific molecular signature. We looked
for and compared molecular species of MCPyV in tumour
and non tumour samples of 33 MCC patients. We showed
that a tumour viral load greater than 1 copy per cell was
associated with a better outcome, and that detection of
the virus in blood but not in urine correlated with a shorter
overall survival. A tumour–specific molecular signature was
found in the blood of two patients with metastatic disease,
but did not occur in their respiratory nor urine samples. We
propose that molecular analysis of MCPyV in tumour and
blood be used as a biomarker of infection and cancer
progression in MCC patients.
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site, and a reverse downstream primer, specific either to the
human integration locus or to the MCPyV non-integrated genome
(Table S1). PCR was performed in 50 ml Ampli Taq Gold Master
Mix (Applied Biosystems) for 50 cycles with conditions specific to
each primer set.
Sequencing
Overlapping fragments of the MCPyV LT encoding gene were
amplified using four primer pairs in order to cover the whole
second exon of LT (base pair number 861 to 3080 according to the
MCV 350 genome (Table S1). PCR was performed on 100 ng
DNA by using HotStartTaq Master Mix kit (Qiagen) containing
0.5 mM primers in a final volume of 50 mL. PCR products were
then directly sequenced as above.
Statistical methods
The cumulative rates of survival in complete remission relative
to MCPyV load in primary MCC (,1o r$1 copy per cell), and
overall survival relative to the presence or absence of MCPyV
DNA in PBMC were estimated by the Kaplan-Meier method.
Patients with follow-up under 3 months were excluded from
analysis. Survival in complete remission was calculated from the
date of diagnosis to the date of first tumour recurrence in patients
AWD or died of disease (DOD) at last follow-up. Patients in
complete remission were censored at their last follow-up visit.
Analyses were performed using the XLStat software (Addinsoft,
Paris, France). Multivariable analysis of survival in complete
remission was done by using a stepwise Cox proportional hazards
model that used forward covariate entry to the model. The
proportions of patients either CR or AWD, or at stages I or II or
III versus IV who had either a MCPyV negative or MCPyV
positive PBMC sample were compared using the exact Fischer
test. All P values were two-sided, and P values less than.05 were
considered statistically significant.
Results
Clinical findings
Thirty nine patients with MCC attended the Dermatology
Departments of Bichat and Cochin hospitals. Six patients without
retrieved MCC material were excluded from the study. The
remaining 33 patients included 14 males and 19 females (sex ratio
=0.6). Their median age at diagnosis was 77 years (range 39–88).
Four patients were immunocompromised, because of corticoid
therapy for rheumatoid arthritis, hepatic transplantation, lympho-
penia and recurring hairy cell leukaemia. Thirteen (39%) patients
had a history of cancer other than MCC (non MCC skin cancer
and/or non skin cancer) (Table S2). Primary MCC was localized
to the limbs, head, and trunk in 21 (64%), 11 (33%) and 1 (3%)
cases respectively. MCC median diameter was 25 mm (range 7–
70 mm). At diagnosis, patients were at Allen’s stages I, II, III and
IV in 9 (27%), 16 (48%), 7 (21%) and 1 (3%) cases respectively
[36]. The median delays from diagnosis until inclusion and last
follow-up were 7 months (up to 112 months) and 16 months (up to
134 months) respectively. At last follow-up, 18 (54%) patients were
in CR, 8 (24%) patients were AWD and 7 (21%) patients had died
of disease (DOD) (Table 1).
MCPyV DNA viral load in MCC samples and outcome
We analyzed 43 MCC samples consisting of 26 primary MCC
(15 fresh-frozen and 11 formalin fixed paraffin-embedded (FFPE)
specimens), 14 skin metastasis (12 fresh-frozen and 2 FFPE
specimens) and 3 fresh-frozen regional lymph node metastasis
samples. Viral DNA was detected in 41/43 samples from 31/33
patients, with a median viral load quantified in 37 samples of 3
copies per cell (range 3.10
23 to 3.10
3). Negative results observed in
one FFPE section and one fresh frozen sample from primary MCC
were confirmed using the previously described LT3 and VP1 PCR
assays [7]. In twenty four patients with follow up greater than
three months, viral load in the primary tumour was analyzed with
respect to survival. Median survival in complete remission was
longer in patients who had $1 copy per cell (n=15), than in
patients who had no detectable viral DNA (n=2) or ,1 copy per
cell (n=7) (34 months, 95% CI =26 to 42 vs 10 months, 95% CI
=7 to 14, Kaplan Meier log-rank P=0.037) (Figure 1). Among
clinical parameters analyzed (sex, age, limb site and size of primary
tumour, and presence or absence of lymph node metastases at
diagnosis), which didn’t differ in the two groups, only female sex
was associated with a better outcome. Adjusted for sex, the relative
hazard for survival in complete remission was 4.8 (95% confidence
interval 0.90–26, P=0.066) with primary tumour containing more
than 1 copy per cell.
MCPyV DNA in non tumour samples of MCC patients,
disease stage and outcome
We then asked if, in MCC patients, MCPyV was restricted to
MCC tissue. Viral DNA was detected in 27/28 (96%) nasal swabs
from 21/21 patients, with a median load of 3.10
3 copies per
sample (range 5–2.10
6). MCPyV DNA was also found in 22/38
(58%) urine samples from 18/28 (64%) MCC patients, with a
median load of 6.10
2 copies/ml (range 100–4.10
5). In addition,
MCPyV was amplified from 20/49 (41%) PBMC samples from
15/30 (50%) patients with a median load of 10
2 copies per ml
whole blood (range 10–5.10
4). MCPyV DNA was detected in 1/6
FFPE non MCC cancer samples from 5 patients (Table S2). We
wondered whether the high rate of detection of MCPyV was
common to other human Polyomaviruses. BKPyV and JCPyV
DNA were amplified from 9% each of nasal swabs, 31% and 7%
of urine samples, and 3% and 6% of PBMC respectively.
Since MCPyV DNA was detected infrequently in urine and in
the PBMC of about half of the patients, we asked whether MCPyV
DNAuria and/or DNAemia were linked to the stage and/or
evolution of the disease. No correlation between MCPyV
detection in urine was found with any of these parameters. In
contrast, detection of MCPyV in PBMC was more frequent in
patients sampled alive with disease (AWD) than in patients in
complete remission (CR) (18/30 or 60% versus 2/19 or 11%,
P=0.00083). Moreover, among AWD patients, MCPyV tended to
be more frequently detected in patients with distant metastasis
than at less advanced stages of the disease (6/6 MCPyV positive
PBMC when sampled at stage IV versus 12/24 or 50% when
sampled at stages I, II or III, P=0.057). In twenty eight patients
with follow up greater than three months, the detection of MCPyV
in PBMC was associated with poorer outcome, since patients with
at least one positive sample had a median survival of 28 months
(95% IC =19 to 36) whereas all patients with no detectable
MCPyV survived after a median follow-up of 71 months (Kaplan
Meier log-rank P=0.003) (Figure 2). All clinical parameters
analyzed were comparable in the PBMC-positive and PBMC-
negative groups except sex, since significantly more male patients
had MCPyV-positive PBMC (P,0.009). Among these parameters,
only primary tumour size above 2 cm was associated with higher
risk of death. We then looked at PBMC results according to viral
load in primary MCC. Among 15 patients with $1 copy per cell,
4/4 patients who relapsed had positive PBMC, compared with 3/
11 disease-free patients. Among 9 patients with ,1 copy per cell, 8
had a PBMC sample tested. Two of four patients who relapsed
MCPyV Signature in Distinct MCC Patients’ Samples
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negative. The four patients who were disease free at last follow-up
had negative PBMC.
MCPyV integration in MCC samples
Using the DIPS-PCR method, we demonstrated the integra-
tion of MCPyV DNA in six MCC cases. We first confirmed
viral integration in metastatic tissue from two patients, and
found virus-host genome junctions identical to those previously
reported in their primary tumours [18]. In three new cases,
integration of MCPyV was found to interrupt the second exon
of LT downstream from the Rb binding coding sequence,
whereas it interrupted the 39 end of the VP1 gene in another
one. Integration was located on four distinct chromosomal loci,
next to or into known human genes (Table 2). Two of them,
PARVA and DENND1A genes, encode proteins involved in
cell junctions and in formation of clathrin coated vesicles or cell
adhesion and cytoskeleton organization respectively. A third
gene, TEAD1, encodes a transcriptional activator reported to
be used by the SV40 enhancer to activate expression of the
early T oncoprotein gene [39]. Finally, in one case, integration
resulted in fusion of the MCPyV LT gene and successive
Table 1. Clinical data of MCC patients.
Case Sex/Age
a Primary MCC data Inclusion visit Last follow-up visit
Size (mm) Site Stage
b Delay
c Status
d Stage
b Delay
c Status
d Stage
b
1 F/74 40 Thigh II 10 AWD III 16 DOD IV
2
e M/81 10 Ankle III 30 AWD III 47 AWD III
3
e M/78 22 Wrist II 15 AWD IV 33 DOD IV
4 F/73 55 Cheek III 1 AWD III 6 CR III
5 F/61 7 Cheek I 25 CR I 26 CR I
6 M/88 25 Leg II 0 AWD II 0 AWD II
7
e M/84 45 Ear II 3 AWD IV 4 DOD IV
8 F/67 10 Cheek I 7 CR I 9 CR I
9
f M/82 10 Mandible I 1 CR I 8 AWD III
10 F/82 21 Leg III 23 CR III 29 CR III
11 F/77 10 Wrist I 0 CR I 0 AWD I
12 M/55 50 Forearm III 5 AWD III 6 AWD III
13 M/71 30 Arm III 24 CR III 24 CR IV
14
e,f M/63 15 Nipple III 0 AWD III 31 CR III
15 F/86 20 Leg IV 1 AWD IV 8 AWD IV
16
f F/77 25 Knee II 7 AWD IV 9 DOD IV
17 F/65 8 Arm I 1 AWD I 4 CR I
18 M/68 20 Thigh II 41 AWD IV 41 DOD IV
19 F/66 30 Thigh II 48 CR II 71 CR II
20 F/85 25 Cheek II 1 AWD II 23 CR II
21 M/60 70 Arm III 4 AWD III 5 CR III
22 F/81 10 Cheek I 35 CR I 41 CR I
23
e M/85 40 Buttock II 21 AWD IV 21 DOD IV
24 F/71 30 Cheek II 37 CR II 37 CR II
25 F/63 10 Cheek I 0 CR I 16 CR II
26 F/39 30 Arm II 112 CR II 134 CR III
27 F/81 15 Thigh I 34 CR I 53 CR I
28 F/58 30 Leg II 1 AWD II 10 CR II
29 F/77 18 Ear I 1 AWD I 10 CR I
30 M/80 40 Vertex II 1 CR II 15 AWD III
31
e,f M/84 27 Thigh II 14 AWD IV 17 DOD IV
32 M/60 45 Arm II 13 AWD III 19 AWD IV
33 F/81 30 Arm II 1 AWD II 3 CR II
aAge at diagnosis.
bDisease stage according to Allen’s classification.
cDelay in months from MCC diagnosis.
dDisease status relative to presence (alive with disease or AWD) or absence (complete remission or CR) of tumour and death (died of disease or DOD).
ePatients partly previously reported [18].
fImmunocompromised patients.
doi:10.1371/journal.ppat.1001076.t001
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GMDS gene, two regions separated by approximately 200 kb
in the human genome, demonstrating that large rearrange-
ments occurred.
Single nucleotide polymorphisms define patients’ strains
We sequenced the whole second exon of LT gene in MCC and
non MCC tissues. Fifty-two sequences from 26 patients displayed
.99% homology with prototypes MCC350, MCC339, MKL-1
and TKS published sequences [7,9]. To characterize strain-
specific and/or tumour-specific markers, a local consensus
reference was constructed by alignment of all sequences, and
variations were indicated as silent, non synonymous or stop
mutations, deletions or insertions. The total number of silent and
non synonymous mutations in MCC and non MCC samples with
respect to the consensus differed by three and sixteen fold
respectively. Single nucleotide polymorphisms (SNPs) character-
ized strain specific signatures in eight patients, and a common
single silent mutation was identified in three other patients
(Figure 3A).
MCC molecular signature differentiates tumour and non
tumour samples
Fourteen MCC sequences (13 complete and 1 partial) were
obtained from 12 patients. In two patients, we verified that
sequences from distinct metastasis exhibited 100% homology.
Mutations which truncate LT were characterized in nine cases,
consisting in stop mutations (5 cases), or deletions causing
frameshifts which generate stop codons (3 cases) (Figure 3A). In
the remaining case, a 250 bp insertion of the third intron of the
DENND1A gene was lying inside LT, upstream the VP1-host
genome junction identified in the second intron of the same
human gene. Overall, mutations preserved the Rb fixation domain
but inactivated the helicase domain of the oncoprotein (Figure 3B).
In one additional patient, we failed to amplify the 39 end 600 last
bp of LT, despite a high viral load and repeated attempts using
different sets of primers, suggesting a truncation of this sequence.
Finally, in the last two cases, full length sequences were obtained
and encoded a non truncated protein. Interestingly, in 5 MCC
cases where the DIPS-PCR characterized integrated-truncated
LT, a complete LT sequence was amplified downstream the
Figure 1. Kaplan Meier analysis of survival in complete remission relative to primary tumour MCPyV load. Patients with $1 genome
copy per cell (n=15, black curve) had longer survival in complete remission than patients with ,1 genome copy per cell (n=9, grey curve). VL : viral
load. Open circles indicate patients censored at last follow-up visit.
doi:10.1371/journal.ppat.1001076.g001
Figure 2. Kaplan Meier analysis of overall survival relative to MCPyV detection in PBMC. Patients who had all MCPyV-negative PBMC
(n=14, black curve) had a longer survival than patients who had at least one MCPyV-positive PBMC (n=14, grey curve). Open circles indicate patients
censored at last follow-up visit.
doi:10.1371/journal.ppat.1001076.g002
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mers or latent episomes of the MCPyV genome and truncated-
integrated viral sequences.
Then, we analyzed 16 nasal and 8 urine sequences. All sequences
were complete except three obtained from weak positive samples,
probably reflecting sensitivity limits of the method used rather than
truncations. Two sequential nasal sequences from the same case
showed 100% homology. All full-length sequences were wild-type.
None of the 9 non MCC samples from 7 patients who displayed a
truncated LT in MCC harboured the tumour-specific molecular
Table 2. Identification of four novel integration sites of MCPyV DNA in MCC genome.
Case
MCPyV 39
breakpoints
a
Chromosome
insertion site Putative target human gene
Gene Distance
4 2166 (LT) 15q14 ATP binding domain 4 isoform 2 (ATPBD4)
Hypothetical protein XP_002343377 (mRNA similar to cytochrome c oxidase,
subunit VIc)
353 kbp (59)
672 kbp (39)
16 3337 (VP1) 9q33 DENN/MADD domain containing 1A isoform 1 (DENND1A)
mir601
2nd intron
600 bp (39)
20 2981 (LT) 11p15 Parvin alpha (PARVA)
TEA domain family member 1 (TEAD1) or SV40 transcriptional enhancer factor
8k b p( 5 9)
228 kbp (39)
29 2594 (LT) 6p24 GDP-mannose 4,6 deshydratase (GMDS) 7th/10th introns
39 virus-host junction was characterized by DIPS PCR.
aBase-pair designations correspond to the prototype MCV 350 (accession number NC_010277). LT = Large T, VP1 = Major viral capsid.
doi:10.1371/journal.ppat.1001076.t002
Figure 3. Characterization of MCC patients’ strain and tumour signature in MCPyV LT. A. Direct PCR sequencing of the second exon of
MCPyV LT in MCC tumours. Twelve distinct representative cases (case number indicated on the left) are represented. Sequences from MCC (black),
nasal swab (blue), urine (green) and PBMC (red) tissues reveal single nucleotide polymorphisms (SNPs), and tumour-specific mutations: open circle,
synonymous; filled circle, non synonymous; black cross, premature stop codon; filled box, deletions. In cases 1 and 20, weak viral load in PBMC and
nasal swab respectively prevented full length amplification of LT. Base pair designation as in Table 2. B. Diagram representation of main functional
domains encoded by the second exon of LT (Rb = Rb binding domain, NLS = nuclear localization signal, OBD = origin binding domain and helicase
domain). Arrows indicate premature truncating mutations determined by direct sequencing and arrowheads indicate the site of integrated viral DNA
determined by 39 DIPS-PCR. GenBank accession number: HM587427-HM587448.
doi:10.1371/journal.ppat.1001076.g003
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are likely to containMCPyV DNAfrom either excreted or episomal
virus.
PBMC sequences were obtained in 14 cases, including partial
sequences obtained from 7 weak positive samples. Complete
PBMC and MCC sequences from 4 patients were compared
(Figure 1A). In one case, both PBMC and MCC sequences
encoded intact LT antigen open reading frame (ORF). In another
case, the premature stop codon observed in MCC LT was absent
from MCPyV recovered from PBMC. In contrast, in two other
cases, the specific MCC signatures (a 5 and a 25 bp deletion
respectively) were recovered from the two patients’ PBMC
samples. Notably, in one of these patients, sequences from nasal
swabs and urine were also analyzed and didn’t harbour the
tumour signature. Since the two patients presented disseminated
metastatic lesions at the time of sampling and were both DOD at
the end of the study, we assume that the presence of mutated
MCPyV DNA in PBMC reflected circulation of metastatic MCC
cells. To further confirm this last hypothesis, we amplified a
portion of the LT gene bracketing the predicted integration site
and the viral-host junction sequence in tumour and non tumour
samples of five patients. Virus-host junction sequences were
amplified from MCC tissue in all cases, from PBMC in two cases,
but from neither urine nor nasal swabs. Both integrated and non
integrated products were amplified from MCC samples, further
suggesting the coexistence of integrated-truncated viral sequences
and integrated concatemers or episomes in MCC samples.
Altogether, these results suggest that MCPyV sequences recovered
at peripheral urine and respiratory sites merely correspond to free
excreted virus or episomal DNA, whereas the presence in the
patients’ PBMC of tumour-like sequences argued for the presence
of circulating tumour cells.
Discussion
Since the discovery by Feng et al who identified MCPyV in 6/8
MCC [7], several large studies have demonstrated that MCPyV is
associated with most cases of MCC except in Australia
[11,12,13,17,19,22,24,26,33]. We detected MCPyV in MCC
from 31/33 patients. Negative results from FFPE specimens could
be due to poor conservation of DNA. Only one fresh frozen
tumour tested negative. We estimated MCC median viral load at 3
copies per cell, with a 6 log variation between samples, consistent
with other reports [13,18,22,40,41,42,43]. Variations may be due
to tissue quality, the proportion of non tumour cells in samples, or
mutations in the target viral sequence. However, variations in rates
of LT expressing MCC cells were also reported [8,43]. The fact
that some MCC cases do not contain MCPyV DNA nor express
LT suggests that MCC is a heterogeneous disease with at least two
etiologies, despite a lack of phenotypic markers able to distinguish
between MCPyV positive and MCPyV negative cases [8,44].
Interestingly, patients with MCC containing at least 1 copy of viral
genome per cell had better outcome than patients with lower
values of MCPyV. Although the low number of patients studied
impairs definite conclusions, it is striking that two previous studies
also reported poorer survival rate in patients with the lowest viral
DNA load and LT expression in MCC [22,40]. Although the
mechanisms of MCC pathogenesis are unknown, variations in
MCPyV load and in patients outcome further argue for
heterogeneity and variable implication of the virus in the disease
[11,12,16,21,45], as previously described in HPV related and
unrelated carcinoma [46]. Several observations support the causal
role of MCPyV in most MCC. In particular, cell transformation
by MCPyV was shown to depend on LT, as in other
polyomaviruses-induced oncogenesis [1]. First, MCPyV LT is
able to bind and sequester the tumor-suppressor protein Rb
through a conserved LxCxE motif [9]. Second, the transformed
phenotype of MCPyV-positive MCC cell lines depends on LT
expression, since cells undergo growth arrest and/or death upon
LT silencing [47]. However, in two models of adenovirus and
polyomavirus-induced oncogenesis, the dependence of trans-
formed cells on viral oncoproteins was reversed upon time, since
cells conserved an oncogenic phenotype while viral expression was
shut-down in one case and viral sequences were lost in the other
[48,49]. These findings suggest that transformed cells acquire
subsequent genetic alterations which circumvent their need for a
continued expression of viral oncoproteins. Therefore, more
cellular genetic alterations may be necessary in virus-unrelated
than in virus-related oncogenesis. In this respect, the number of
chromosomal alterations and amplifications was significantly
higher in HPV-unrelated than in HPV-related carcinomas, and
correlated with unfavourable prognosis [46]. Recurrent genomic
changes have been described in MCC [16,18], but their link with
MCPyV has not yet been extensively investigated.
Monoclonal integration of MCPyV is viewed as a key element
in oncogenesis. We identified in metastatic lesions from two
patients the same virus-host genome integration characteristics
previously described in their primary tumours, sustaining the
hypothesis that viral integration constitutes an early event in MCC
oncogenesis [7,18]. We also showed the integration of truncated
LT in four cases, and in one of these this led to a complex
rearrangement between LT, VP1 and the target human gene. All
chromosomal integration sites identified so far differ from each
other [7,18]. We are currently verifying whether expression of
putative target human genes, located in the vicinity or at the site of
integration, is modified in tumour cells, notably TEAD1 which
was reported to be used by another Polyomavirus, SV40, as a
transcriptional enhancer factor. In addition, MCC LT sequences
revealed various point or frameshift mutations which preserve the
Rb binding domain but truncate the oncoprotein before the
helicase domain, as in the tumour-specific molecular signatures
previously described [9,50]. Such truncations preserve the
transformation ability of LT through Rb sequestration, but
prevent viral DNA replication. A similar loss of full-length LT
has been observed in vitro and in vivo in models of SV40 and
MPyV-induced carcinogenesis [51,52] In addition, replication-
defective polyomaviruses with loss of LT binding to the origin of
replication showed enhanced transforming properties [53]. Our
results extend previous observations and reinforce the hypothesis
that acquisition of mutations within LT is a common feature and
may be a prerequisite for carcinogenesis induced by polyoma-
viruses. However, in three cases of this series and in two previously
reported cases, mutations truncated LT upstream an identified
nuclear localization signal, which could prevent nuclear expression
of the protein [9]. Lastly, mutations in LT were not observed in all
cases in this nor in other studies [43,54]. We can’t exclude that
these cases display mutations at other sites critical for MCPyV
replication. A point mutation in a pentanucleotide sequence of the
replication origin was observed in a MCC strain and prevented
replication [55]. Finally, the fact that the full length second exon of
LT was sequenced in five MCC samples although integration
interrupted LT suggests that, as previously observed with Southern
Blot analysis [9], truncated/integrated and probably whole
genomic copies of MCPyV coexist in tumour cells, as confirmed
by PCR assay which discriminates integrated versus non
integrated MCPyV genomes.
The lifecycle of MCPyV in the host is unknown. Serological
studies showed that infection is common in the general population
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of MCC. Routes of transmission and sites of excretion are not
completely known. We showed presence of MCPyV in the
respiratory tract of most MCC patients, in serial samples drawn at
a several-month interval, in contrasts with low detection rate
(below 17%) in non MCC patients reported in the literature and
observed with our own detection method (data not shown)
[4,27,28,50,56,57,58]. MCPyV DNA excretion in urine, which
was previously reported in one MCC case [59], was observed in
almost half of patients, above rates (below 25%) reported in
control subjects [23,26]. Comparative LT sequencing from MCC
and non MCC samples revealed strain-specific SNPs. Whereas
most MCC sequences displayed tumour-specific molecular
signatures, all nasal swabs and urine sequences were wild-type,
suggesting that the latter correspond to excreted or episomal virus,
whereas the former belong to integrated genomes. Thus, high
rates of MCPyV excretion both in the respiratory tract and urine
may be a hallmark of MCC patients. Urine excretion of BKPyV or
JCPyV is frequent in immune competent subjects and increases
with age, during pregnancy or immune suppression [60,61]. Since
excretion rates of BKPyV and JCPyV were comparable in MCC
patients to rates of non MCC patients [61,62], we hypothesize that
patients present a specific failure to control latency of MCPyV but
not all Polyomaviruses. This hypothesis is supported by the fact
that high levels of antibodies directed towards the major viral
capsid protein VP1 of MCPyV but not other human Polyoma-
viruses were more frequently observed in MCC patients than in
the general population [31,34]. Indeed, in the case of BKPyV and
JCPyV infection, reactivation and active shedding were positively
correlated with serum antibody responses to VP1 [63,64].
Lastly, our results show evidence of high rates of MCPyV DNA
in MCC patients’ PBMC, in contrast with low rates (0–8%)
reported in the serum, whole blood or PBMC of non MCC
subjects [17,19,27,29,50]. Moreover, MCPyV DNA detection in
PBMC was significantly correlated with the disease stage and
outcome since patients with at least one PBMC positive sample
had shorter survival in remission that patients in whom MCPyV
had not been detected in any PBMC sample. In one patient,
MCPyV recovered from PBMC had a wild-type genotype whereas
the viral genome recovered from MCC had a LT truncating
mutation. We hypothesize that MCPyV DNAemia may corre-
spond to active viral replication following reactivation, as observed
with other human polyomaviruses [2,61]. Indeed, MCPyV DNA
detection was reported in activated circulating monocytes of one
MCC patient and one control [59]. In two patients in our study
however, viral sequences recovered from PBMC displayed the
patient’s MCC-specific molecular signature. As both patients were
sampled at a metastatic stage and subsequently died of their
disease, we believe that PBMC viral DNA revealed metastatic
circulating cells, since MCC cells were previously identified in the
peripheral blood of one MCC patient [65].
Altogether, our results provide new insights in the life cycle of
MCPyV during MCC pathogenesis. The low number of cases
studied might weaken the statistical power of our results. However,
we suggest that quantitative and qualitative molecular analysis of
MCPyV in tumour and non tumour sites of MCC patients may be
a useful tool to characterize their disease stage and manage their
follow-up. We are currently designing a prospective study to
confirm these results in large series of patients.
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